Table 1 Demographics of the patients enrolled in the training and validation sets
Characteristics | Training set (35) | Validation set (22) | P-value |
|---|---|---|---|
Age (years) | 0.187 | ||
 ≤ 60 | 16 (45.71%) | 14 (63.64%) |  |
 > 60 | 19 (54.29%) | 8 (36.36%) |  |
Gender | 0.339 | ||
 Female | 17 (48.57%) | 7 (31.82%) |  |
 Male | 18 (51.43%) | 15 (68.18%) |  |
Race | 0.946 | ||
 Others | 3 (8.57%) | 2 (9.09%) |  |
 White | 32 (91.43%) | 20 (90.91%) |  |
KPS score | 0.538 | ||
  > 60 | 25 (71.43%) | 14 (63.64%) |  |
  ≤ 60 | 10 (28.57%) | 8 (36.36%) |  |
Subtype | 0.915 | ||
 Classical | 10 (28.57%) | 6 (27.27%) |  |
 N-Classical | 25 (71.43%) | 16 (72.73%) |  |
CIMP | 0.635 | ||
 G-CIMP | 2 (5.71%) | 2 (9.09%) |  |
 NON G-CIMP | 33 (94.29%) | 20 (90.91%) |  |
IDH | 1.000 | ||
 Mutant | 4 (11.43%) | 2 (9.09%) |  |
 Wild-type | 31 (88.57%) | 20 (90.91%) |  |
Radiotherapy | 1.000 | ||
 Yes | 4 (11.43%) | 2 (9.09%) |  |
 No | 31 (88.57%) | 20 (90.91%) |  |
Pharmaceutical | 1.000 | ||
 Yes | 5 (14.29%) | 3 (13.64%) |  |
 No | 30 (85.71%) | 19 (86.36%) |  |
Status | 1.000 | ||
 Alive | 3 (8.57%) | 2 (9.09%) |  |
 Dead | 32 (91.43%) | 20 (90.91%) |  |
Survival time | 1.24 ± 1.23 | 1.62 ± 1.55 | 0.261 |